Magnetic immunosensor with trench configuration and method of use
The present invention provides apparatus and methods for the rapid determination of analytes in liquid samples by immunoassays incorporating magnetic capture of beads on a sensor capable of being used in the point-of-care diagnostic field.
1 . A point-of-care magnetic immunosensing device, comprising:
a cartridge housing comprising a base;
a sample chamber comprising a sample inlet for receiving a sample;
a conduit in fluidic communication with the sample chamber;
a sensor chip located within the conduit and formed on the base of the cartridge housing, wherein the sensor chip comprises a single sensing electrode comprising: a) a silicon wafer, b) a single trench formed in the silicon wafer; a dissolvable dry matrix comprising magnetically susceptible beads, wherein the matrix is configured to dissolve in the sample fluid; and
a permanent high-field magnet; and
a pump for moving the sample from the sample chamber through the conduit to the sensing electrode,
wherein the single trench comprises a two-dimensional array of microfabricated electrodes comprising a line of microelectrodes.
2 . The device of claim 1 , wherein the single trench has a length of from 10 to 500 μm.
3 . The device of claim 1 , wherein the magnetically susceptible beads have an average particle size of from about 0.01 μm to about 20 μm.
4 . The device of claim 1 , wherein the magnetically susceptible beads comprise ferrite.
5 . The device of claim 1 , wherein the magnetically susceptible beads comprise magnetite (Fe 3 O 4 ).
6 . The device of claim 1 , wherein the magnetically susceptible beads comprise a magnetically susceptible core with a polymer coating.
7 . The device of claim 1 , wherein the magnetically susceptible beads are coupled to an antibody in the dissolvable dry matrix.
8 . The device of claim 7 , wherein the antibody is to an analyte selected from the group consisting of cardiac troponin I, troponin T, a troponin complex, human chorionic gonadotropin, BNP, creatine kinase, creatine kinase subunit M, creatine kinase subunit B, creatine kinase MB (CK-MB), proBNP, NT-proBNP, myoglobin, and myosin light chain-thereof.
9 . The device of claim 7 , wherein the antibody is to an analyte selected from the group consisting of beta-HCG, TSH, ultra hTSH II, TT3, TT4, FT3, FT4, myeloperoxidase, D-dimer, CRP, NGAL, PSA, LH, FSH, prolactin, progesterone, estradiol, DHEA-S, AFP, CA 125 II, CA 125, CA 15-3, CA 19-9, CA 19-9XR, CEA, thyroxine (T4), triiodothyronine (T3), T-uptake, Tg, anti-Tg, anti-TPO, ferritin, cortisol, insulin, HBsAg, HCV Ag/Ab combo, HCV core Ag, anti-HCV, AUSAB (anti-HBs), CORE, CORE-M, SHBG, iPTH, theophylline, sirolimus, tacrolimus, anti-HAV, anti-HAV IgM, HAVAB, HAVAB-M, HAVAB-M2.0, HAVAB-G, HAVAB 2.0, HAVAB 2.0 Quant, IgM, CMV IgM, CMV IgG, â-2-microglobulin, digitoxin, HBe, anti-HBe, HBeAg, HIV 1/2gO, HIV Ag/Ab combo, testosterone, SCC, vitamin B12, folate, syphilis, anti-HBc, rubella IgG, rubella IgM, homocysteine, MPO, cytomegalovirus (CMV) IgG Avidity, toxo IgG avidity, toxo IgG, toxo IgM, C-peptide, vitamin D, HTLV I/II, total âhCG, progesterone, estradrogen, prolactin, myoglobin, tPSA, fPSA, carbamazepine (CBZ), digoxin, gentamicin, NAPA, phenytoin, phenobarbital, valproic acid, vancomycin, procaine, quinidine, tobramycin, methamphetamine (METH), amphetamine (AMPH), barbiturates, benzodiazepine, cannabis, cocaine, methadone, opiates, PCP, acetaminophen, ethanol, salicylates, tricyclics, holoTc, anti-CCP, HbA1c, and barbs-U.
10 . The device of claim 1 , wherein the magnetically susceptible beads are mobile within the trough of the single trench.
11 . The device of claim 1 , wherein the ratio of the magnetically susceptible beads within the trough of the single trench to electrodes of the electrode array is about 1.
12 . The device of claim 1 , wherein the sample is amended with an anticoagulant.
13 . The device of claim 1 , wherein the width to height ratio of the single trench is in the range of about 0.1 to about 5.
14 . The device of claim 1 , wherein the permanent high-field magnet is positioned in a non-coplanar position relative to said electrode array.
15 . The device of claim 1 , wherein the permanent high-field magnet is positioned below said electrode array.
16 . The device of claim 1 , wherein the permanent high-field magnet comprises a neodymium iron boron (NdFeB) alloy.
17 . The device of claim 1 , wherein the permanent high-field magnet is a bulk magnet.
18 . The device of claim 1 , wherein the permanent high-field magnet is a substantially cylindrical bulk magnet, having a diameter in the range of about 0.1 mm to about 5 mm and a length of about 0.1 mm to about 5 mm.
19 . The device of claim 1 , wherein the average width, height and length of the single trench are each at least twice the mean average particle size of the magnetically susceptible beads.
20 . The device of claim 1 , wherein the device comprises the sample chamber coated within the dissolvable dry matrix, wherein the sample chamber is connected to the conduit between the sample inlet and the two-dimensional array.